Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
6.50    0.02 (0.30%)
Bid:
6.00
Ask:
7.00
Spread: 1.00 (16.667%)
Market Cap: £425.55m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Notification under AIM Rule Schedule Two (g)

9 Oct 2013 08:48

RNS Number : 0827Q
Allergy Therapeutics PLC
09 October 2013
 



9 October 2013

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

Notification under AIM Rule Schedule Two (g)

 

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, makes the following update announcement under AIM Rule Schedule Two (g) regarding Stephen Smith, a non-executive director of Allergy Therapeutics plc.

 

In addition to being a non-executive director of the Company, Stephen Smith acts as a 'company doctor' working with companies in distressed situations and in some cases the role has required a restructuring through a pre-planned administration/receivership or a planned insolvency to ensure an orderly winding down of the business. In providing these services, Stephen Smith was appointed as a director of the companies listed below in Table 1 which had administrators, receivers or liquidators appointed. These companies were part of the following groups:

 

· Texon International Group where Stephen Smith was appointed a director in 2004 and subsequently there was a restructuring in 2005 through a receivership which created a viable group where he continues to be a director.

 

· Ethel Austin Group where Stephen Smith was appointed a director in 2005. In 2008 lenders sold their secured loans to a company which appointed administrators a few days later.

 

· The Food & Drink Group where Stephen Smith was appointed a director in 2008 and administrators were appointed in 2009 in a pre-planned process to achieve a sale of the profitable parts of the business.

 

· Paramount Restaurants Group where Stephen Smith was appointed a director in 2011 and later that year arranged a restructuring and subsequent pre-planned administration to achieve disposals of the profitable parts of the group.

 

· Ennstone plc where Stephen Smith was appointed a director in 2008 and administrators were appointed in 2009 to complete a restructuring which ensured the viability of the UK and European businesses and protected the US business via a Chapter 11 process.

 

Table 1

 

Company

Comments

ACLM Limited (in administration)

Part of Ethel Austin Group

Bluelodge Limited (in administration)

Part of The Food & Drink Group

Burlington Restaurant Limited (in administration)

Part of The Food & Drink Group

Ennstone plc (in administration)

Holding company

Enterprises Realisations Limited (in administration)

Part of The Food & Drink Group

Ethel Austin Retail Group Limited (in administration)

Part of Ethel Austin Group

Ethel Austin Retail Holdings Limited (in administration)

Part of Ethel Austin Group

Futurestar Limited (in administration)

Part of The Food & Drink Group

Group Realisations Limited (in administration)

Part of The Food & Drink Group

Hartford Operations Limited (in administration)

Part of The Food & Drink Group

J Bar Limited (in administration)

Part of The Food & Drink Group

Montana plc (in administration)

Part of The Food & Drink Group

Newtaste Restaurants Limited (in administration)

Part of The Food & Drink Group

Noteframe Limited (in administration)

Part of Ethel Austin Group

Noxet Administration Services Limited

Part of Texon International group

PWC Realisations Limited (in administration)

Part of The Food & Drink Group

Texon Group Limited

Part of Texon International group

Texon Holdings Ltd (in liquidation)

Part of Texon International group

Texon International Limited

Part of Texon International group

The Food & Drink Group plc (in administration)

Part of The Food & Drink Group

USM (Holdings) Ltd

Part of Texon International group

Vantis Financial Management Limited (in administration)

Part of Vantis group

Vantis plc (in administration)

Part of Vantis group

Caffe Uno Brasseries Limited (in administration)

Part of Paramount Restaurants group

Charlotte Street Restaurants Limited

Part of Paramount Restaurants group

Chez Gerard Restaurants Limited (in administration)

Part of Paramount Restaurants group

Craftbutton Limited (in administration)

Part of Paramount Restaurants group

Groupe Chez Gerard Limited (in administration)

Part of Paramount Restaurants group

Groupe Chez Gerard Restaurants Limited (in administration)

Part of Paramount Restaurants group

Leviathan Limited (in liquidation)

Part of Paramount Restaurants group

Paramount Acquisitions Limited (in liquidation)

Part of Paramount Restaurants group

Paramount Holdings Limited (in administration)

Part of Paramount Restaurants group

Paramount Limited (in administration)

Part of Paramount Restaurants group

Paramount Restaurants Limited (in administration)

Part of Paramount Restaurants group

Smile Restaurants Limited (in liquidation)

Part of Paramount Restaurants group

 

 

-Ends-

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 821

Ian Postlethwaite

Finance Director

Manuel Llobet

Chief Executive Officer

www.allergytherapeutics.com

Peel Hunt LLP

+44 (0) 20 7418 8900

James Steel / Dr. Vijay Barathan

FTI Consulting

+44 (0) 207 831 3113

Simon Conway / Victoria Foster Mitchell

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFSDIRLAIIV
Date   Source Headline
24th Oct 20238:29 amRNSForm 8.5 (EPT/RI)
23rd Oct 20238:23 amRNSForm 8.5 (EPT/RI)
20th Oct 20235:17 pmRNSHolding(s) in Company
20th Oct 20239:02 amRNSForm 8.5 (EPT/RI)
19th Oct 20238:38 amRNSForm 8.5 (EPT/RI)
19th Oct 20237:00 amRNSPosting of Offer Document
18th Oct 20238:34 amRNSForm 8.5 (EPT/RI)
17th Oct 202310:31 amRNSForm 8.5 (EPT/RI)
16th Oct 20235:39 pmRNSSouthern Fox: Form 8.3 – Allergy Therapeutics Plc
16th Oct 20233:03 pmRNSHolding(s) in Company
16th Oct 20232:42 pmRNSForm 8.5 (EPT/RI)
16th Oct 202312:42 pmRNSForm 8.5 (EPT/NON-RI)
16th Oct 202311:17 amRNSForm 8 (DD) - Allergy Therapeutics plc
16th Oct 20238:29 amRNSForm 8.5 (EPT/RI)
16th Oct 20238:01 amRNSUnconditional Mandatory Cash Offer
13th Oct 20237:00 amRNSResult of Open Offer and Subscription
12th Oct 20238:34 amRNSForm 8.5 (EPT/RI)
11th Oct 20238:35 amRNSForm 8.5 (EPT/RI)
10th Oct 20238:13 amRNSForm 8.5 (EPT/RI)
9th Oct 20238:44 amRNSForm 8.5 (EPT/RI)
5th Oct 20238:42 amRNSForm 8.5 (EPT/RI)
4th Oct 20238:42 amRNSForm 8.5 (EPT/RI)
3rd Oct 20238:16 amRNSForm 8.5 (EPT/RI)
2nd Oct 20235:53 pmRNSBlock Listing Interim Review
2nd Oct 20239:36 amRNSForm 8.5 (EPT/RI)
29th Sep 20239:19 amRNSForm 8.5 (EPT/RI)
29th Sep 20238:46 amRNSForm 8.5 (EPT/NON-RI)
28th Sep 20238:52 amRNSForm 8.5 (EPT/RI)
27th Sep 202312:04 pmRNSPublication of Open Offer Circular – Amendment
27th Sep 202310:45 amRNSForm 8.5 (EPT/NON-RI)
27th Sep 20237:01 amRNSPublication of Open Offer Circular
27th Sep 20237:00 amRNSUnaudited Preliminary Results 2023
26th Sep 20238:36 amRNSForm 8.5 (EPT/RI)
26th Sep 20237:00 amRNSPhase I VLP Peanut PROTECT trial progress
25th Sep 20239:07 amRNSForm 8.5 (EPT/RI)
22nd Sep 20239:59 amRNSForm 8.5 (EPT/NON-RI)
22nd Sep 20237:35 amRNSForm 8.5 (EPT/RI)
22nd Sep 20237:00 amRNSSatisfaction of FDI clearance conditions
21st Sep 202310:34 amRNSForm 8.5 (EPT/NON-RI)
21st Sep 20238:13 amRNSForm 8.5 (EPT/RI)
18th Sep 20238:16 amRNSForm 8.5 (EPT/RI)
15th Sep 20233:14 pmRNSForm 8.5 (EPT/NON-RI)
15th Sep 20239:02 amRNSForm 8.5 (EPT/RI)
14th Sep 20237:33 amRNSForm 8.5 (EPT/RI)
13th Sep 20237:39 amRNSForm 8.5 (EPT/RI)
12th Sep 20237:00 amRNSForm 8.5 (EPT/RI)
11th Sep 20231:01 pmRNSForm 8.5 (EPT/RI)
8th Sep 20238:57 amRNSForm 8.5 (EPT/RI)
7th Sep 20238:38 amRNSForm 8.5 (EPT/RI)
6th Sep 20238:45 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.